Dr. Ivo Abraham named editor of medical economics journal
Ivo Abraham, PhD, RN, a professor of practice at the University of Arizona R. Ken Coit College of Pharmacy, was named editor in chief of the Journal of Medical Economics.
Dr. Abraham has been a full-time faculty member since 2010.
The journal publishes peer-reviewed articles from within the pharmacoeconomics, healthcare research and health insurance communities. The journal aims to help translate economic research into clinical practice and bring greater awareness to high-quality economic assessments of novel therapeutic and device interventions for a global audience.
Ivo Abraham, PhD, RN
Pharmacoeconomics evaluates the value of pharmaceutical treatments. Researchers in this field analyze the costs and benefits of treatment options to inform healthcare providers, insurers and policymakers about which therapies to use while managing healthcare costs.
In his role at the journal, Dr. Abraham said he will focus on publishing articles from around the world aimed at the effectiveness of treatments in relation to their costs.
“We want to focus more on the relationship between what care is provided to the patient, the quality of that care, and the cost,” he said. “Basically, providing the best possible care in a cost-responsible and justifiable way.”
“We have a stringent peer review process, and the editorial team reads every paper submitted for consideration to ensure the author’s conclusions are the result of good analytical practices,” said Dr. Abraham. “In economic analysis, it’s all about assumptions, so we want to make sure these assumptions are defensible.”
Dr. Abraham, who was deputy editor in chief of the journal for the three years before being named editor in chief, said that he hopes his new role will help bring greater visibility to the Coit College of Pharmacy and the university as a whole.
“This has been the best academic job I’ve had, and I am enormously grateful,” he said. “I hope all our academic programs and especially the students in the health and pharmaceutical outcomes program will benefit from this visibility.”